Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
FATE
#3071
Fate Therapeutics, Inc.
1.4
8
+2.07%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+2.07%
Aylık değişim
+12.12%
6 aylık değişim
+28.70%
Yıllık değişim
+39.62%
Önceki kapanış
1.4
5
Open
1.4
8
Bid
Ask
Low
1.4
8
High
1.4
8
Hacim
50
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
FATE
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
113.89 M
114.6 M
114.63 M
115.33 M
115.35 M
116.26 M
—
Valuation ratios
Enterprise value
360.72 M
153.03 M
45.65 M
87.92 M
104.72 M
67.62 M
305.92 M
Price to earnings ratio
-2.12
-1.01
-0.53
-0.77
-0.95
-0.85
-3.11
Price to sales ratio
29.21
13.76
6.94
15.49
20.71
—
—
Price to cash flow ratio
2.85
1.53
0.75
1.13
1.34
1.1
4.32
Price to book ratio
0.24
0.59
0.07
0.11
0.13
0.56
0.87
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.1
0.12
0.09
0.09
0.09
0.1
0.38
Return on equity %
0.13
0.16
0.13
0.13
0.14
0.16
0.55
Return on invested capital %
—
-13.31
—
—
—
-79.08
—
Gross margin %
100
100
100
100
100
100
400
Operating margin %
1 703.87
3 319.78
2 534.07
1 938.54
1 995.12
2 536.23
9 003.96
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
1 551.01
2 803.92
2 309.45
1 786.58
1 852.38
2 364.79
8 313.2
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
8.29
7.58
8.81
8.04
7.87
5.79
30.51
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.01
0
0
0
0
0
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
0.25
0.24
0.29
0.21
0.2
0.2
0.89
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
2.52
0.32
2.03
1.88
1.81
1.71
7.44
Net current asset value per share
2.63
2.57
2.1
1.94
1.86
1.76
7.66
Tangible book value per share
3.08
2.8
2.44
2.21
1.97
1.74
8.35
Working capital per share
2.32
2.23
1.86
1.7
1.62
1.45
6.64
Book value per share
3.08
2.8
2.44
2.21
1.97
1.74
8.35
Haberler
Baird réitère sa note sur l’action Fate Therapeutics après les progrès des essais
Baird reiterates Fate Therapeutics stock rating on trial progress
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Le BPA de Fate Therapeutics a dépassé les attentes, le CA a surpassé les prévisions
Fate Therapeutics earnings beat, revenue topped estimates
Fate Therapeutics reports positive lupus treatment data at ASH meeting
Le BPA de Fate Therapeutics a dépassé les attentes de 0,03$, le CA a surpassé les prévisions
Fate Therapeutics earnings beat by $0.03, revenue topped estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates